Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lisocabtagene Maraleucel
Drug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255
Procedure: X-Ray Imaging
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Lumbar Puncture
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2022-05-03

Last Posted Date: 2024-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05359211

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Genotype-guided Treatment in DLBCL

Phase 3

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Orelabrutinib
Drug: Lenalidomide
Drug: Decitabine

First Posted Date: 2022-04-28

Last Posted Date: 2023-03-24

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 1100

Registration Number: NCT05351346

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Phase 1

Active, not recruiting

Conditions: Advanced Lung Non-Small Cell Carcinoma
Refractory Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8

Interventions: Biological: Antineoplastic Immune Cell
Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-04-19

Last Posted Date: 2024-05-29

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 6

Registration Number: NCT05334329

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematologic Neoplasms

Interventions: Procedure: donor lymphocyte infusion
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Mycophenolate mofetil
Drug: Fludarabine
Drug: Sirolimus

First Posted Date: 2022-04-14

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 430

Registration Number: NCT05327023

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: fhB7H3.CAR-Ts
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-12

Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University

Target Recruit Count: 15

Registration Number: NCT05323201

Locations: 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions: Drug: Orelabrutinib
Drug: Obinutuzumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-19

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 25

Registration Number: NCT05322733

Locations: 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Phase 3

Recruiting

Conditions: Embryonal Rhabdomyosarcoma
Fusion-Negative Alveolar Rhabdomyosarcoma
Spindle Cell/Sclerosing Rhabdomyosarcoma

Interventions: Procedure: Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Cyclophosphamide
Biological: Dactinomycin
Procedure: Magnetic Resonance Elastography
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Drug: Vincristine

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 205

Registration Number: NCT05304585

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 155 locations

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Dexamethasone
Biological: Inotuzumab Ozogamicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Methylprednisolone
Biological: Rituximab
Drug: Prednisone
Drug: Mercaptopurine
Drug: Doxorubicin

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 66

Registration Number: NCT05303792

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States

and more 66 locations

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Phase 4

Conditions: Systemic Sclerosis

Interventions: Drug: Cyclophosphamide
Drug: Baricitinib

First Posted Date: 2022-03-29

Last Posted Date: 2022-03-29

Lead Sponsor: Tongji Hospital

Target Recruit Count: 60

Registration Number: NCT05300932

Locations: 🇨🇳
Department of RheumatologyTongji Hospital, Wuhan, Hubei, China
🇨🇳
Tongji Hospital, Wuhan, Hubei, China

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1

Recruiting

Conditions: Ovary Cancer
Non Small Cell Lung Cancer
Sarcoma,Soft Tissue
Melanoma Stage IV
Sarcoma, Synovial
Metastatic Cancer
Bladder Urothelial Carcinoma
Triple Negative Breast Cancer
Neuroblastoma, Metastatic

Interventions: Drug: CYCLOPHOSPHAMIDE and FLUDARABIN
Drug: Cyclophosphamide
Biological: HBI 0201-ESO TCRT
Drug: Aldesleukin

First Posted Date: 2022-03-25

Last Posted Date: 2023-09-25

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 3

Registration Number: NCT05296564

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy